Immunocore to present at the Jefferies London Healthcare Conference
Immunocore Holdings Plc (Nasdaq: IMCR) will present at the Jefferies London Healthcare Conference on November 17, 2022, at 9:45 a.m. GMT. The presentation will be available via live webcast on Immunocore's website and a replay will follow temporarily. As a pioneering biotechnology company, Immunocore develops T cell receptor (TCR) bispecific immunotherapies targeting various diseases, including cancer. Their advanced treatment, KIMMTRAK, is approved for metastatic uveal melanoma in several key markets.
- None.
- None.
Immunocore to present at the Jefferies London Healthcare Conference
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 10 November 2022) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infection and autoimmune disease, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference.
The presentation is scheduled for Wednesday, November 17, 2022, at 9:45 a.m. Greenwich Mean Time (GMT).
The presentation will be webcast live during the conference and will be available in the ‘Investors’ section of Immunocore’s website at www.immunocore.com. A replay of the presentation will be made available for a limited time.
##
About Immunocore
Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune, and infectious disease. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. Immunocore’s most advanced oncology TCR therapeutic, KIMMTRAK, has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM) in the United States, European Union, Canada, Australia and the United Kingdom, having demonstrated an overall survival benefit in a randomized Phase 3 clinical trial in mUM, a cancer that has historically proven to be insensitive to other immunotherapies.
CONTACT:
Immunocore
Sébastien Desprez, Head of Communications
T: +44 (0) 7458030732
E: sebastien.desprez@immunocore.com
Follow on Twitter: @Immunocore
Consilium Strategic Communications (corporate and financial)
Mary-Jane Elliott/ Chris Welsh/Jessica Hodgson
T: +44 (0)203 709 5700
E: Immunocore@consilium-comms.com
Investor Relations
Clayton Robertson, Head of Investor Relations
T: +1 215-384-4781
E: ir@immunocore.com
FAQ
When will Immunocore present at the Jefferies London Healthcare Conference?
Where can I watch Immunocore's presentation during the Jefferies London Healthcare Conference?
What is the stock symbol for Immunocore?
What is KIMMTRAK and its approval status?
What type of company is Immunocore?
